Trinity Capital Inc. Provides $15 Million in Growth Capital to Cagent Vascular Inc.
Trinity Capital (NASDAQ: TRIN) has committed $15 million in growth capital to Cagent Vascular, a medical device company specializing in serration technology for vessel dilation in endovascular interventions. This funding complements a $45 million equity financing round led by US Venture Partners in 2024.
Cagent Vascular's flagship product, Serranator®, enhances angioplasty procedures by providing more controlled lumen gain with minimal dissection while reducing vessel recoil. The technology has been utilized in over 20,000 procedures and will use the new funding to scale commercial infrastructure and accelerate clinical adoption.
Trinity Capital (NASDAQ: TRIN) ha impegnato 15 milioni di dollari in capitale di crescita per Cagent Vascular, un'azienda di dispositivi medici specializzata nella tecnologia di serraggio per la dilatazione dei vasi nelle interventi endovascolari. Questo finanziamento integra un round di finanziamento azionario da 45 milioni di dollari guidato da US Venture Partners nel 2024.
Il prodotto di punta di Cagent Vascular, Serranator®, migliora le procedure di angioplastica fornendo un guadagno del lume più controllato con una dissezione minima e riducendo il rimbalzo del vaso. La tecnologia è stata utilizzata in oltre 20.000 procedure e utilizzerà i nuovi fondi per espandere l'infrastruttura commerciale e accelerare l'adozione clinica.
Trinity Capital (NASDAQ: TRIN) ha comprometido 15 millones de dólares en capital de crecimiento para Cagent Vascular, una empresa de dispositivos médicos especializada en tecnología de serrado para la dilatación de vasos en intervenciones endovasculares. Este financiamiento complementa una ronda de financiamiento de capital de 45 millones de dólares liderada por US Venture Partners en 2024.
El producto principal de Cagent Vascular, Serranator®, mejora los procedimientos de angioplastia al proporcionar un aumento del lumen más controlado con una disección mínima y reduciendo el retroceso del vaso. La tecnología ha sido utilizada en más de 20,000 procedimientos y utilizará los nuevos fondos para escalar la infraestructura comercial y acelerar la adopción clínica.
트리니티 캐피탈 (NASDAQ: TRIN)은 1500만 달러의 성장 자본을 카겐트 혈관에 투자했습니다. 카겐트 혈관은 혈관 내 시술을 위한 혈관 확장을 위한 절단 기술을 전문으로 하는 의료 기기 회사입니다. 이 자금은 2024년에 US Venture Partners가 주도한 4500만 달러의 주식 자금 조달 라운드를 보완합니다.
카겐트 혈관의 주력 제품인 Serranator®는 최소한의 절개로 보다 통제된 내강 증가를 제공하여 혈관 성형술 절차를 향상시킵니다. 이 기술은 20,000건 이상의 시술에 사용되었으며, 새로운 자금을 상업적 인프라를 확장하고 임상 도입을 가속화하는 데 사용할 것입니다.
Trinity Capital (NASDAQ: TRIN) a engagé 15 millions de dollars en capital de croissance pour Cagent Vascular, une entreprise de dispositifs médicaux spécialisée dans la technologie de sération pour la dilatation des vaisseaux lors des interventions endovasculaires. Ce financement complète un tour de financement par actions de 45 millions de dollars dirigé par US Venture Partners en 2024.
Le produit phare de Cagent Vascular, Serranator®, améliore les procédures d'angioplastie en offrant un gain de lumière plus contrôlé avec une dissection minimale tout en réduisant le recul des vaisseaux. La technologie a été utilisée dans plus de 20 000 procédures et utilisera les nouveaux fonds pour développer l'infrastructure commerciale et accélérer l'adoption clinique.
Trinity Capital (NASDAQ: TRIN) hat 15 Millionen Dollar in Wachstumskapital für Cagent Vascular bereitgestellt, ein Unternehmen für medizinische Geräte, das sich auf Serration-Technologie zur Gefäßerweiterung bei endovaskulären Eingriffen spezialisiert hat. Diese Finanzierung ergänzt eine Finanzierungsrunde über 45 Millionen Dollar, die 2024 von US Venture Partners geleitet wurde.
Das Flaggschiffprodukt von Cagent Vascular, Serranator®, verbessert die Angioplastie-Verfahren, indem es einen kontrollierteren Lumen-Zuwachs mit minimaler Dissektion bietet und die Gefäßrückfederung reduziert. Die Technologie wurde in über 20.000 Verfahren eingesetzt und wird die neuen Mittel nutzen, um die kommerzielle Infrastruktur auszubauen und die klinische Einführung zu beschleunigen.
- Secured $15 million in growth capital financing
- Previously raised $45 million in equity financing in 2024
- Serranator® technology already used in over 20,000 procedures
- None.
Insights
The $15 million growth capital commitment to Cagent Vascular represents a calculated bet on next-generation vascular treatment technology, particularly noteworthy following the company's substantial $45 million equity round led by US Venture Partners. The sequential funding structure - equity followed by growth capital - suggests strong commercial traction and reduced technical risk.
The Serranator® technology addresses a critical need in the $2.5 billion peripheral artery disease treatment market. Its unique serration approach to vessel dilation potentially offers superior outcomes compared to traditional balloon angioplasty, with over 20,000 successful procedures providing substantial clinical validation. This track record significantly de-risks the investment while suggesting strong physician adoption.
For Trinity Capital, this investment aligns with their strategy of backing commercially-validated medical technologies with clear paths to market expansion. The combination of established clinical use, strong institutional backing, and focused commercial scaling objectives presents an attractive risk-reward profile. The structure as growth capital rather than equity suggests confidence in near-term revenue generation potential.
The investment's timing is particularly strategic as healthcare systems increasingly prioritize minimally invasive procedures that can reduce complications and improve patient outcomes. Cagent's focus on controlled lumen gain with minimal dissection addresses both clinical and economic benefits that healthcare providers seek in new technologies.
Cagent Vascular is a medical device company pioneering innovative vascular treatment technologies. The company's flagship product, Serranator®, helps improve angioplasty procedures by providing more predictable and controlled lumen gain with minimal dissection, while mitigating vessel recoil. Cagent Vascular aims to enhance patient outcomes and advance minimally invasive interventions by developing advanced endovascular solutions.
"We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease," said Ryan Kaeding, Managing Director, Life Sciences at Trinity Capital.
"Cagent Vascular's Serration technology has been used in over 20,000 procedures and offers a growing library of compelling clinical evidence. We're confident this additional capital will help scale our commercial infrastructure and further accelerate clinical adoption," said Brian Walsh, Chairman and CEO of Cagent Vascular. "Trinity Capital's support is appreciated as we build a leading vascular company and make a difference in the lives of patients around the globe."
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio. With distinct business verticals, Trinity Capital stands as a trusted partner for innovative companies seeking tailored growth capital solutions. Headquartered in
About Cagent Vascular Inc.
Cagent Vascular Inc., founded and led by serial medical technology entrepreneurs, is the leader in Serration Technology to treat peripheral artery disease. The company has developed a transformative improvement to conventional angioplasty, which is the most commonly performed procedure to restore blood flow. Although angioplasty has been used clinically for over 50 years, there remain significant opportunities to optimize the therapy and to improve the treatment outcomes of cardiovascular disease. To learn more about Cagent Vascular's mission to fight PAD, visit www.cagentvascular.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-15-million-in-growth-capital-to-cagent-vascular-inc-302380496.html
SOURCE Trinity Capital Inc.
FAQ
How much growth capital did Trinity Capital (TRIN) provide to Cagent Vascular in February 2024?
What is the total funding raised by Cagent Vascular including Trinity Capital's investment?
How many procedures has Cagent Vascular's Serranator® technology been used in?
What will Cagent Vascular use Trinity Capital's (TRIN) funding for?
